Modality
ASO
MOA
SGLT2i
Target
PCSK9
Pathway
Notch
GBMAsthma
Development Pipeline
Preclinical
~May 2022
→ ~Aug 2023
Phase 1
~Nov 2023
→ ~Feb 2025
Phase 2
May 2025
→ Feb 2028
Phase 2Current
NCT07659913
2,577 pts·GBM
2025-05→2028-02·Recruiting
2,577 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-02-121.9y awayPh2 Data· GBM
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3Q42028
P2
Recruit…
Catalysts
Ph2 Data
2028-02-12 · 1.9y away
GBM
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07659913 | Phase 2 | GBM | Recruiting | 2577 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 |